Daridorexant 50 mg
DrugDaridorexant 50 mg (Orally administered)
NCT Number: NCT07532252
This study will test whether the dual orexin receptor antagonist (DORA) daridorexant reduces alcohol craving and use and improves total sleep time among patients with co-occurring alcohol use disorder and sleep disturbance. The study will assess the role of the orexin system in modulating alcohol craving and use in a real-world treatment setting.
Trial opening soon.
Get Notified18 year and older
All sexes
Interventional
Phase 2
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Daridorexant 50 mg (Orally administered)
Placebo (Oral)
Time frame: Enrollment to one month follow-up
Total sleep time will be assessed through both wireless EEG and ambulatory monitoring. Wireless EEG will be assessed during the residential phase only. Ambulatory monitoring will occur during both the residential and outpatient phase.
Time frame: Enrollment to one month follow-up
Visual Analogue Scales assessing alcohol craving will be administered (Range 0-100, higher scores indicate greater craving).
Time frame: Outpatient phase (Day 1 post-residential treatment to one-month follow-up)
Time frame: From enrollment to one month follow-up
Time frame: Outpatient phase (Day 1 post-residential treatment to one-month follow-up)
Time frame: Outpatient phase (Day 1 post-residential treatment to one-month follow-up)
Time frame: Enrollment to one-month follow-up
Alcohol use disorder symptoms, assessed using the Alcohol Use Disorders module of the Mini-International Neuropsychiatric Interview. 9-items rated on a dichotomous Yes/No scale.
Time frame: Enrollment to one-month follow-up
Self-reported insomnia severity, assessed using the Insomnia Severity Index. Each item is scored 0 (no problem) - 4 (very big problem) likert scale with total score range between 0-28 (absence of insomnia (0-7); sub-threshold insomnia (8-14); moderate insomnia (15-21); and severe insomnia (22-28).
Contact information is provided by the study sponsor or research team.
Johns Hopkins University
Other
A Double-Blind Randomized Controlled Trial of Daridorexant for Alcohol Use Disorder
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06790342
Alcohol Use Disorder, Alcohol-Related Disorders
Nairobi, Kenya
View Trial DetailsNCT07678567
Alcohol Use Disorder, Alcohol-Induced Disorders
Louisville, Kentucky, United States
View Trial DetailsNCT07218354
Alcohol Use Disorder, Alcohol-Related Disorders
Long Beach, California, United States
View Trial DetailsNCT07701928
Alcohol Use Disorder, Alcohol-Related Disorders
Spokane, Washington, United States
View Trial Details